Stockscreener 앱 받기
10.75
11.16%
-1.35
시간 외 거래:
10.87
0.12
+1.12%
전일 마감가:
$12.10
열려 있는:
$11.75
하루 거래량:
4.14M
Relative Volume:
1.90
시가총액:
$1.13B
수익:
$69.65M
순이익/손실:
$-81.27M
주가수익비율:
-11.83
EPS:
-0.9088
순현금흐름:
$-79.45M
1주 성능:
-5.70%
1개월 성능:
+93.35%
6개월 성능:
+12.45%
1년 성능:
+112.45%
1일 변동 폭
$10.38
$11.95
1주일 범위
$10.37
$12.53
52주 변동 폭
$3.84
$12.53
Personalis Inc Stock (PSNL) Company Profile
명칭
Personalis Inc
전화
650-752-1300
주소
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
10.75 | 1.27B | 69.65M | -81.27M | -79.45M | -0.9088 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-05-15 | 개시 | Guggenheim | Buy |
| 2025-03-17 | 개시 | Craig Hallum | Buy |
| 2023-02-06 | 업그레이드 | Needham | Hold → Buy |
| 2022-01-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | 다운그레이드 | Needham | Buy → Hold |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-20 | 재확인 | Needham | Buy |
| 2021-05-06 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2021-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-12 | 재확인 | Needham | Buy |
| 2020-11-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-08-27 | 개시 | H.C. Wainwright | Buy |
| 2020-08-18 | 개시 | Needham | Buy |
| 2019-09-26 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | 개시 | BofA/Merrill | Neutral |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Morgan Stanley | Overweight |
| 2019-07-15 | 개시 | Oppenheimer | Outperform |
모두보기
Personalis Inc 주식(PSNL)의 최신 뉴스
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Personalis (NASDAQ: PSNL) CFO sells 40,000 shares under 10b5-1 plan - Stock Titan
Personalis CFO Aaron Tachibana sells $480,400 in company stock - Investing.com
Aaron L. Tachibana (PSNL) exercises 40,000 options; prior 38,799 10b5-1 sale - Stock Titan
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors? - Yahoo Finance
Personalis Data Highlights Early Cancer Recurrence Detection - Clinical Lab Products
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 - BioSpace
Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum - Yahoo Finance
Personalis Insider Sold Shares Worth $449,292, According to a Recent SEC Filing - marketscreener.com
Personalis CEO Christopher M. Hall sells $1.1m in stock By Investing.com - Investing.com India
Personalis CEO Christopher M. Hall sells $1.1m in stock - Investing.com
Personalis CFO and COO Aaron Tachibana sells $449,292 in stock By Investing.com - Investing.com Australia
Personalis CFO and COO Aaron Tachibana sells $449,292 in stock - Investing.com
Personalis (NASDAQ: PSNL) CEO sells 100K shares after exercising options - Stock Titan
Personalis (PSNL) CFO sells shares via pre-set Rule 10b5-1 plan - Stock Titan
Personalis (PSNL) Is Up 34.5% After CMS Expands NeXT Personal MRD Test Medicare Coverage - simplywall.st
Personalis stock hits 52-week high at $11.51 By Investing.com - Investing.com Australia
[144] Personalis, Inc. SEC Filing - Stock Titan
Personalis, Inc. Hits Day High with 15.7% Surge in Stock Price - Markets Mojo
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating (NASDAQ:PSNL) - Seeking Alpha
ETFs Investing in Personalis, Inc. Stocks - TradingView
Personalis gains after fourth Medicare coverage win for NeXT Personal - MSN
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium - BioSpace
Personalis Inc. (PSNL) Rallies 2.67% as Volume Picks Up – Key Levels in SightFair Value Gap - thelegaladvocate.com
Personalis Inc. (PSNL) Surges 4.5% as Stock Tests Key Resistance Near $9.05Overnight Profile - thelegaladvocate.com
Craig-Hallum Maintains Personalis(PSNL.US) With Buy Rating - Moomoo
Personalis outlines 2026 clinical volume target of 43,000 to 45,000 tests while reaffirming $78M to $80M revenue guidance - MSN
Personalis NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid - Moomoo
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Medicare Expands Coverage for Personalis NeXT Personal Test - TipRanks
US agency broadens coverage of Personalis breast cancer test - MSN
Expanded Medicare covers Personalis (NASDAQ: PSNL) NeXT Personal cancer test - Stock Titan
Personalis gains expanded Medicare coverage for breast cancer test By Investing.com - Investing.com Nigeria
US Agency Broadens Coverage Of Personalis Breast Cancer Test - Benzinga
Personalis Shares Rise After NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid - marketscreener.com
Personalis (PSNL) Shares Climb on Expanded Medicare Coverage for NeXT Personal Test - GuruFocus
Personalis (PSNL) Expands Medicare Coverage for NeXT Personal Te - GuruFocus
Personalis gets expanded Medicare coverage for NeXT Personal - Seeking Alpha
Personalis secures fourth Medicare coverage decision for Next Personal, expanding breast cancer coverage to pre-surgical treatment monitoring - marketscreener.com
Personalis gains expanded Medicare coverage for breast cancer test - Investing.com
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring - Business Wire
Personalis rises as Medicare coverage for NeXT Personal test expands - MSN
Personalis Inc (PSNL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.13%
2.22%
자본화:
|
볼륨(24시간):